Association between cannabis use and clinical outcomes in patients with solid malignancies receiving immune checkpoint inhibitors.

Ther Adv Vaccines Immunother · 2024 · PMC11683815 · PMID 39737331

Europe PMC DOI

hedged sentences

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

did not reach statistical significancep = 0.08so close (0.05 < p ≤ 0.1)

The median OS was numerically higher in the CAN nonusers (54.9 vs 23.6 months) but did not reach statistical significance ( p = 0.08).

also in 111,027 other papers

showed a trendno p-value reported

25 Another more homogeneous study of non-small-cell lung cancer (NSCLC) patients receiving pembrolizumab monotherapy showed a trend toward worse OS among CAN users with no effect on PFS. 26 Interestingly, are-analysis of the former two studies noted some unreported significant differences between the CAN users and non-users, which could have confounded the concluded results. 27 In addition, all of these studies have used very high doses of plant-based CAN, such high doses are not typically used in the United States.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.